Venous Thromboembolism Prophylaxis Who, when and what?
Venous Thromboembolism Prophylaxis Who, when and what?
Venous Thromboembolism Prophylaxis Who, when and what?
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Thromboprophylaxis of Medical Patients<br />
Clear benefits over placebo<br />
Study RRR NNT <strong>Prophylaxis</strong> Pts with VTE,<br />
%<br />
MEDENOX<br />
n=1102<br />
PREVENT<br />
n=3706<br />
ARTEMIS<br />
n=849<br />
63% 10 Placebo<br />
Enoxaparin<br />
40mg<br />
45% 45 Placebo<br />
Dalteparin<br />
47% 20 Placebo<br />
Fondaparinux<br />
14.9<br />
5.5<br />
5.0<br />
2.8<br />
10.5<br />
5.6<br />
Samama MM, et al. N Engl J Med 1999; 341: 793-800<br />
Leizorovicz A, et al. Circulation 2004; 110: 874-9<br />
Cohen AT, et al. J Thromb Haemostat 2003; 1: Suppl 1: 2046
Change language